Myeloproliferative Disorders

Myeloproliferative Disorders Content

COVID-19, Anaemia, Leukaemia, Myeloproliferative Disorders, Haematological Malignancies, Myelodysplastic Syndrome, Paediatric Haematology, Rare Diseases, Thrombocytopenia, White Blood Cell Disorders, Genetic Blood Disorders, Amyloidosis, Autoimmune Blood Disorders, Blood and Bone Marrow Transplantation, Bloodstream Infections, Haemostatic Disorders, Lymphoma, Maternal-foetal Medicine, Myeloma, Platelet Disorders, Policy, Transfusion Medicine

What’s on the horizon for continuing medical education? Insights from touchIME

In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.

Myeloproliferative Disorders, Anaemia, Rare Diseases, Thrombocytopenia

touchPANEL DISCUSSION

Tailoring treatment in myelofibrosis: Addressing anaemia and thrombocytopenia

CE/CME ACCREDITED Prof. Haifa Kathrin Al-Ali, Prof. Alessandro Vannucchi, Prof. Jean-Jacques Kiladjian Translations available:

Three experts discuss the burden of myelofibrosis and anaemia/thrombocytopenia and targeted treatment options.

Supporting haematology patient care: Insights from the Haematology Nurses and Healthcare Professionals Group

Nurses account for the largest group of professionals in the healthcare system and there are an estimated 29 million nurses worldwide (WHO, 2024). Nursing practice needs to be dynamic in order to respond to the changing needs of an aging population and the increasing incidence of chronic diseases (WHO, 2022; Hacker, 2024). Within the haematology […]

Anaemia, Myeloproliferative Disorders, Myelodysplastic Syndrome, Paediatric Haematology, Lymphoma

#ASH24: Discover the 2024 late-breaking abstracts

The American Society of Hematology (ASH) held its 66th Annual Meeting from 7–10 December 2024. Among the highlights of the meeting were six late-breaking abstracts that have the potential to influence how healthcare professionals approach a range of condition,s from introducing new or altering current practice. These include disorders such as lymphoma, sickle cell anaemia […]

Myeloproliferative Disorders

Combination therapy in myelofibrosis: John Mascarenhas on the IMpactMF trial

The IMpactMF trial is a phase 1/1b study evaluating the addition of Imetelstat to ruxolitinib for myelofibrosis patients who show an inadequate response to ruxolitinib alone. By combining these therapies earlier in treatment, the study aims to assess safety, tolerability and potential efficacy, offering hope for improved outcomes. In this interview, touchHAEMATOLOGY Editorial Board member […]

Myeloproliferative Disorders

Navtemadlin in myelofibrosis: Advancing treatment with MDM2 inhibition

John Mascarenhas Watch Time: 9 mins

Join editorial board member Dr John Mascarenhas (Icahn School of Medicine at Mount Sinai, New York, NY, USA) as he explores the potential of navtemadlin, an oral MDM2 inhibitor, as a treatment option for myelofibrosis. He discusses thehey take-aways from the BOREAS study, including its disease-modifying impact in patients relapsed or refractory to JAK inhibitors, […]

Myeloproliferative Disorders

Laying the groundwork for medical breakthroughs: The MPN-RC blueprint

John Mascarenhas

Few alliances have impacted patient care as significantly as the Myeloproliferative Neoplasms Research Consortium (MPN-RC). Established in 2006, the MPN-RC is an international group dedicated to advancing research and developing innovative treatment strategies for myeloproliferative neoplasms (MPNs). In this episode, we speak with John Mascarenhas, MD, about the coalition's founding, operational mechanics and how their efforts have led to paradigm-shifting therapies in the field.

Myeloproliferative Disorders

Potential of elritercept (KER-050) to treat myelofibrosis: RESTORE trial

Claire Harrison Watch Time: 8 mins

The phase II RESTORE trial evaluated elritercept (KER-050), an investigational treatment for myelofibrosis (MF) and ruxolitinib-associated cytopenias. Elritercept, targeting specific transforming growth factor-beta (TGF-β) ligands to improve haematopoiesis, was tested alone and in combination with ruxolitinib. In Part 1 (N=41), the trial assessed safety, tolerability, pharmacokinetics, and efficacy across doses (0.75-4.5 mg/kg). Results showed a 37% transfusion dependency among participants, with common adverse events including diarrhoea (22%), thrombocytopaenia (17%) and fatigue (15%). The recommended dose for Part 2 was 3.75 mg/kg, up-titrated to 5.0 mg/kg. Erythropoiesis improved in non-transfusion-dependent participants, with 54% showing increased hemoglobin (Hgb). Transfusion burden was reduced by ≥50% in 38% of transfusion-dependent participants. Additionally, spleen size and symptom scores decreased in 57% and 67% of evaluable participants, respectively. Elritercept showed potential to treat MF-related anemia, cytopenias, and splenomegaly, warranting further analysis.

Leukaemia, Myeloproliferative Disorders, Myelodysplastic Syndrome, Lymphoma, Myeloma

EHA 2024: Highlights of the late-breaking abstracts

The EHA 2024 congress has once again united top haematology experts from around the globe. This year's event featured plenty of innovations and developments, from novel therapies to cutting-edge genetic studies. In this article we provide an overview of the late-breaking abstracts presented at the meeting.

Feedback

Feedback

FILTER YOUR SEARCH

Content Type:

Speciality:

Conference:

Myeloproliferative Disorders